title: HIV-associated hematologic disorders are correlated with plasma viral load and improve under highly active antiretroviral therapy.
abstract: The relationship between HIV-1 replication and hematologic parameters was examined in two separate studies. The first study was a cross-sectional evaluation of 207 untreated patients. In this study, the proportion of patients with hematologic disorders increased with disease progression. There was a significant inverse correlation between HIV-1 plasma viral load and all hematologic values (r = -0.266 to -0.331). The second study was a longitudinal evaluation of patients on combination antiretroviral therapy (HAART) with hematologic alterations before treatment ( N = 27 with platelets <150,000/microl, 24 with hemoglobin <12 g/dl, 36 with neutrophils <2000/microl and 29 with leukocytes <3000/microl). Samples were analyzed every 3 months for 2 years. At 2 years, >50% of patients experienced a sustained virologic response, with viral loads <500 RNA copies/ml. Hematologic reconstitution occurred progressively for all blood cell lineages and became statistically significant after the sixth month of therapy ( p <.001). Mean values increased from 110 to 180 x 10(3)/microl for platelets, from 10.7 to 12.3 g/dl for hemoglobin (stabilizing finally at 11.4 g/dl), from 1,260 to 2,240/microl for neutrophils, and from 2,260 to 3,600/microl for leukocytes. In conclusion, hematologic disorders are corrected by combination antiretroviral therapy. This suggests a causative role of HIV-1 in hematologic disorders.
authors.affiliation: Laboratoire de Rétrovirologie, Centre de Recherche Public-Santé, Luxembourg.
authors.forename: J
authors.initials: J
authors.lastname: Servais
authors.forename: D
authors.initials: D
authors.lastname: Nkoghe
authors.forename: J C
authors.initials: JC
authors.lastname: Schmit
authors.forename: V
authors.initials: V
authors.lastname: Arendt
authors.forename: I
authors.initials: I
authors.lastname: Robert
authors.forename: T
authors.initials: T
authors.lastname: Staub
authors.forename: M
authors.initials: M
authors.lastname: Moutschen
authors.forename: F
authors.initials: F
authors.lastname: Schneider
authors.forename: R
authors.initials: R
authors.lastname: Hemmer
mesh_terms: D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D003430:Cross-Sectional Studies; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy / Q000821:virology*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D015497:HIV-1 / Q000187:drug effects / Q000502:physiology*; D006402:Hematologic Diseases / Q000188:drug therapy / Q000209:etiology / Q000821:virology*; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D019562:Viral Load; D014779:Virus Replication
chemical_list: D017320:HIV Protease Inhibitors